Filtered By:
Condition: Autoimmune Disease

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 584 results found since Jan 2013.

Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis
CONCLUSION: A weighted GRS for SLE was associated with an increased risk of several autoimmune-related phenotypes including type I diabetes but not with cardiometabolic disorders.PMID:33977795 | DOI:10.1177/09612033211014952
Source: Lupus - May 12, 2021 Category: Rheumatology Authors: Vivian K Kawai Mingjian Shi Ge Liu QiPing Feng WeiQi Wei Cecilia P Chung Theresa L Walunas Adam S Gordon James G Linneman Scott J Hebbring John B Harley Nancy J Cox Dan M Roden C Michael Stein Jonathan D Mosley Source Type: research

COVID ‐19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study
ConclusionOur findings indicate that COVID ‐19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission, acute renal failure, and venous thromboembolism when compared to COVID‐19 patients without systemic ARDs. These risks may be largely mediated by comorbidities, except for the risk of venous thromboembolism .
Source: Arthritis and Rheumatology - May 1, 2021 Category: Rheumatology Authors: Kristin M. D ’Silva, April Jorge, Andrew Cohen, Natalie McCormick, Yuqing Zhang, Zachary S. Wallace, Hyon K. Choi Tags: Brief Report Source Type: research

Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review
Semin Thromb Hemost DOI: 10.1055/s-0040-1722270Glucocorticoids are potent anti-inflammatory agents that are widely used for the treatment of many inflammatory, autoimmune, and neoplastic disorders. However, their beneficial effect is associated with several side effects, including an increased risk of cardiovascular complications, such as myocardial infarction and stroke. Whether their use also contributes to a procoagulant state, and therefore increases the risk of venous thromboembolism (VTE), is still a matter of debate. As an increased risk of venous thrombotic events is described in patients with Cushing's syndrome, w...
Source: Seminars in Thrombosis and Hemostasis - April 23, 2021 Category: Hematology Authors: Simion, Chiara Campello, Elena Bensi, Elisa Bellio, Andrea Pontarin, Anna Spiezia, Luca Simioni, Paolo Tags: Review Article Source Type: research

Clinical and radiological aspects of bilateral temporal abnormalities: pictorial essay
Abstract The temporal lobes are vulnerable to several diseases, including infectious, immune-mediated, degenerative, vascular, metabolic, and neoplastic processes. Therefore, lesions in the temporal lobes can pose a diagnostic challenge for the radiologist. The temporal lobes are connected by structures such as the anterior commissure, corpus callosum, and hippocampal commissure. That interconnectedness favors bilateral involvement in various clinical contexts. This pictorial essay is based on a retrospective analysis of case files from a tertiary university hospital and aims to illustrate some of the conditions that simul...
Source: Radiologia Brasileira - March 26, 2021 Category: Radiology Source Type: research

Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins ’ Mimicry of Human Protein Interactions
Conclusion: SARS-CoV-2-human protein interactions may lead to the development of delirium, psychosis, seizures, encephalitis, stroke, sensory impairments, peripheral nerve diseases, and autoimmune disorders. Our findings are also supported by the previous in vivo and in vitro studies from other viruses. Further in vivo and in vitro studies using the proteins that are pointed here, could pave new targets both for avoiding and reversing neuropsychiatric presentations.
Source: Frontiers in Human Neuroscience - March 23, 2021 Category: Neuroscience Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cutting the "Gordian Knot" - Cardiac Involvement in Primary Sj ögren Syndrome
J Rheumatol. 2021 Mar 15:jrheum.201171. doi: 10.3899/jrheum.201171. Online ahead of print.ABSTRACTSjögren syndrome (SS) is a systemic autoimmune disease typically characterized by inflammatory involvement of the exocrine glands1 The association of SS with an increased risk of cardiovascular disease (CVD) including manifestations such as stroke and myocardial infarction has been demonstrated by numerous previous studies1.PMID:33722948 | DOI:10.3899/jrheum.201171
Source: J Rheumatol - March 16, 2021 Category: Rheumatology Authors: George Markousis-Mavrogenis Sophie I Mavrogeni Source Type: research